D. E. Shaw & Co., Inc. Voyager Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 118,828 shares of VYGR stock, worth $672,566. This represents 0.0% of its overall portfolio holdings.

Number of Shares

118,828

Holding current value

$672,566

% of portfolio

0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$5.77 - $9.27 $500,680 - $804,385	-86,773 Reduced 42.2%	118,828 $695,000
Q2 2024 Aug 14, 2024	SELL	$7.42 - $10.54 $210,638 - $299,209	-28,388 Reduced 12.13%	205,601 $1.63 Million
Q1 2024 May 15, 2024	SELL	$7.15 - $10.84 $1.23 Million - $1.87 Million	-172,055 Reduced 42.37%	233,989 $2.18 Million
Q4 2023 Feb 14, 2024	SELL	$6.28 - $8.81 $1.38 Million - $1.94 Million	-220,079 Reduced 35.15%	406,044 $3.43 Million
Q3 2023 Nov 14, 2023	SELL	$7.55 - $11.25 $2.43 Million - $3.62 Million	-321,850 Reduced 33.95%	626,123 $4.85 Million
Q2 2023 Aug 14, 2023	BUY	$6.94 - $13.99 $2.22 Million - $4.47 Million	319,501 Added 50.84%	947,973 $10.9 Million
Q1 2023 May 15, 2023	SELL	$6.0 - $10.78 $361,368 - $649,257	-60,228 Reduced 8.75%	628,472 $4.85 Million
Q4 2022 Feb 14, 2023	SELL	$4.94 - $6.61 $79,415 - $106,262	-16,076 Reduced 2.28%	688,700 $4.2 Million
Q3 2022 Nov 14, 2022	SELL	$5.57 - $7.47 $124,578 - $167,074	-22,366 Reduced 3.08%	704,776 $4.17 Million
Q2 2022 Aug 15, 2022	BUY	$4.82 - $10.09 $438,239 - $917,392	90,921 Added 14.29%	727,142 $4.3 Million
Q1 2022 May 16, 2022	BUY	$2.75 - $9.44 $941,044 - $3.23 Million	342,198 Added 116.38%	636,221 $4.85 Million
Q4 2021 Feb 14, 2022	BUY	$2.47 - $5.55 $726,236 - $1.63 Million	294,023 New	294,023 $797,000
Q3 2020 Nov 16, 2020	SELL	$10.01 - $13.75 $199,469 - $273,996	-19,927 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$8.05 - $14.21 $135,046 - $238,386	-16,776 Reduced 45.71%	19,927 $251,000
Q1 2020 May 15, 2020	SELL	$6.8 - $14.66 $1.04 Million - $2.25 Million	-153,303 Reduced 80.68%	36,703 $336,000
Q4 2019 Feb 14, 2020	BUY	$12.82 - $16.85 $187,428 - $246,347	14,620 Added 8.34%	190,006 $2.65 Million
Q3 2019 Nov 14, 2019	SELL	$16.31 - $28.29 $1.44 Million - $2.49 Million	-88,076 Reduced 33.43%	175,386 $3.02 Million
Q2 2019 Aug 14, 2019	BUY	$19.18 - $27.88 $438,397 - $637,253	22,857 Added 9.5%	263,462 $7.17 Million
Q1 2019 May 15, 2019	BUY	$8.0 - $19.66 $1.61 Million - $3.96 Million	201,274 Added 511.74%	240,605 $4.61 Million
Q4 2018 Feb 14, 2019	BUY	$8.59 - $18.05 $337,853 - $709,924	39,331 New	39,331 $370,000
Q4 2017 Feb 14, 2018	SELL	$12.26 - $25.88 $130,213 - $274,871	-10,621 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$8.37 - $20.59 $88,897 - $218,686	10,621	10,621 $219,000

Others Institutions Holding VYGR

# of Institutions

130

Shares Held

34.7M

Call Options Held

39.7K

Put Options Held

34.6K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $219M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account